CoChat

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications

Anderson, Kenneth C., Auclair, Daniel, Kelloff, Gary J., Sigman, Caroline C., Avet-Loiseau, Hervé, Farrell, Ann T., Gormley, Nicole J., Kumar, Shaji K., Landgren, Ola, Munshi, Nikhil C., Cavo, Michele, Davies, Faith E., Di Bacco, Alessandra, Dickey, Jennifer S., Gutman, Steven I., Higley, Howard R., Hussein, Mohamad A., Jessup, J. Milburn, Kirsch, Ilan R., Little, Richard F., Loberg, Robert D., Lohr, Jens G., Mukundan, Lata, Omel, James L., Pugh, Trevor J., Reaman, Gregory H., Robbins, Michael D., Sasser, A. Kate, Valente, Nancy, Zamagni, Elena · 2017 · Clinical Cancer Research
Cited by 91

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Treatment of myeloma has benefited from the introduction of more effective and better tolerated agents, improvements in supportive care, better understanding of disease biology, revision of diagnostic criteria, and new sensitive and specific tools for disease prognostication and management. Assessment of minimal residual disease (MRD) in response to therapy is one of these tools, as longer progression-free survival (PFS) is seen consistently among patients who have achieved MRD negativity. Current therapies lead to unprecedented frequency and depth of response, and next-generation flow and sequencing methods to measure MRD in bone marrow are in use and being developed with sensitivities in the range of 10−5 to 10−6 cells. These technologies may be combined with functional imaging to detect MRD outside of bone marrow. Moreover, immune profiling methods are being developed to better understand the immune environment in myeloma and response to immunomodulatory agents while methods for molecular profiling of myeloma cells and circulating DNA in blood are also emerging. With the continued development and standardization of these methodologies, MRD has high potential for use in gaining new drug approvals in myeloma. The FDA has outlined two pathways by which MRD could be qualified as a surrogate endpoint for clinical studies directed at obtaining accelerated approval for new myeloma drugs. Most importantly, better understanding of MRD should also contribute to better treatment monitoring. Potentially, MRD status could be used as a prognostic factor for making treatment decisions and for informing timing of therapeutic interventions. Clin Cancer Res; 23(15); 3980–93. ©2017 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-2895

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 91

Metadata

Authors
Anderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet-Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., Cavo, M., Davies, F. E., Di Bacco, A., Dickey, J. S., Gutman, S. I., Higley, H. R., Hussein, M. A., Jessup, J. M., Kirsch, I. R., Little, R. F., Loberg, R. D., Lohr, J. G., Mukundan, L., Omel, J. L., Pugh, T. J., Reaman, G. H., Robbins, M. D., Sasser, A. K., Valente, N., & Zamagni, E.
Venue
Clinical Cancer Research
Published
2017-08-01
Volume
23
Issue
15
Pages
3980-3993
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2606664616
Cited by
91
References
9
FWCI
7.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-2895
The paper
Anderson, K. C., Auclair, D., Kelloff, G. J., Sigman, C. C., Avet-Loiseau, H., Farrell, A. T., Gormley, N. J., Kumar, S. K., Landgren, O., Munshi, N. C., Cavo, M., Davies, F. E., Di Bacco, A., Dickey, J. S., Gutman, S. I., Higley, H. R., Hussein, M. A., Jessup, J. M., Kirsch, I. R., . . . Zamagni, E. (2017). The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-2895

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.